

# Cell Therapy-2013: A Catalyst for the Advancement in Cell & Gene Therapies - OMICS Group Medical Conferences

*2nd International Conference and Exhibition on Cell & Gene Therapy to be held during October 23-25 2013, at Orlando-FL, USA.*

LOS ANGELES, CA, USA, August 2, 2013 /EINPresswire.com/ -- Cell Therapy and Gene Therapy are two different fields of biomedical research that often overlaps with similar therapeutic goals. If DNA is inserted to fight an acquired or inherited disease, Cell Transplantation takes place in 'Cell therapy' to fight diseases. Although both the methods have been deployed for the past three decades, technological advancements in the medical field are opening up variety of opportunities to cancers of all kind effectively.

Following methods are widely used in both [Cell and Gene Therapy](#):

- Gene drugs are delivered directly into the tumor to kill Cancer
- Cell and gene Vaccines are injected to resist or destroy Cancer
- Cell and Gene Therapeutics are used to target a particular stem cell to destroy cancer.
- Gene therapy is used to smother the cancer cell by cutting of the blood supply.

Cell Therapy-2013: [OMICS Group](#) takes pride in inviting all the participants across the globe to



2nd International Conference and Exhibition on Cell & Gene Therapy 2013

**Workshop on**  
Cryopreservation and High Temperature Biostabilization  
for Cell and Gene Therapy  
**Igor I. Katkov, Ph.D.**  
Chief Scientific Officer and Founder, Celltronix



Workshop on Cryopreservation and High Temperature Biostabilization for Cell and Gene Therapy by Igor I. Katkov, Ph.D.

attend the 2nd International Conference and Exhibition on Cell & Gene Therapy to be held during October 23-25 2013, at Orlando-FL, USA.

Following the success of the 1st International Conference on Emerging Cell Therapies, OMICS group calls for yet another venture in this area.

Cell Therapy-2013 is a remarkable event which brings together a unique and International mix of leading Universities and cell therapy institutions making the Congress a perfect platform to share experience.

It serve as a catalyst for the advancement in cell & gene therapies by connecting scientists within and across disciplines at conferences held under a single roof that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society.

Reputed speakers that are part of the event are:

- Jagat R. Kanwar, Deakin University Australia
- Kapil Bharti, National Institutes of Health USA
- Paul L Hermonat, Central Arkansas Veterans Healthcare System, USA
- Joseph Pastore, Juventas Therapeutics, USA
- Hilal Arnouk, Cell Constructs, Inc, USA
- Paul D. Robbins, The Scripps Research Institute, USA
- Valentin Fulga, Hemostemix, Canada
- Karim Nayernia, Co-Director of Institute of Molecular Medicine and Cell Therapy, Germany

Major Tracks of the Conference Include

- Cell & Gene Therapy- Potential Applications
- Stem Cell Therapies
- Cellular Therapies
- Advanced Gene Therapeutics
- Immunotherapy
- Cancer Therapies
- Nano-Therapy
- Bioengineering Therapeutics
- Clinical Trials and Research in Cell & Gene Therapies
- Regulatory & Ethical Issues of Therapies

Workshop

Parallel to conference, Igor I. Katkov, Ph. D, Chief Scientific Officer and Founder, Celltronix holds a workshop on "Cryopreservation and High Temperature Biostabilization of cell and Gene Therapy".

For more details on Cell Therapy-2013 Conference, please visit:  
<http://www.omicsgroup.com/conferences/cell-gene-therapy-2013/>

For further details contact  
Sharan Daniel  
Cell Therapy-2013 Organizing Committee  
[Medical Conferences](#)  
5716 Corsa Ave., Suite 110  
Westlake, Los Angeles, CA 91362-7354, USA  
Phone: +1-650-268-9744  
Fax: +1-650-618-1414  
Toll free: +1-800-216-6499  
E-mail: [celltherapy2013@omicsgroup.info](mailto:celltherapy2013@omicsgroup.info)  
[celltherapy2013@omicsgroup.us](mailto:celltherapy2013@omicsgroup.us)

Sharan Daniel  
OMICS Group Incorporation  
+1- 650-268-9744  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/161400343>  
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.  
© 1995-2024 Newsmatics Inc. All Right Reserved.